Dr. Anna Pawlowska, MD
Claim this profileCity of Hope Comprehensive Cancer Center
Studies Cancer
Studies Adult T-Cell Leukemia/Lymphoma
26 reported clinical trials
63 drugs studied
About Anna Pawlowska, MD
Education:
- Holds an MD (Doctor of Medicine).
Experience:
- Currently serves as a Pediatric Hematologist-Oncologist at City of Hope Comprehensive Cancer Center.
- Director of the Pediatric Hematopoietic Cell Transplantation Program at City of Hope.
- Recognized for her specialization in treating young people with leukemia.
Area of expertise
1Cancer
Stage I
Stage II
Stage IV
2Adult T-Cell Leukemia/Lymphoma
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
Affiliated Hospitals
Clinical Trials Anna Pawlowska, MD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Non-TBI Conditioning
for HCT in Acute Lymphoblastic Leukemia
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).
Recruiting1 award Phase 2
More about Anna Pawlowska, MD
Clinical Trial Related8 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Anna Pawlowska, MD has experience with
- Dexamethasone
- Cyclophosphamide
- Pegaspargase
- Prednisolone
- Mercaptopurine
- Methotrexate
Breakdown of trials Anna Pawlowska, MD has run
Cancer
Adult T-Cell Leukemia/Lymphoma
Lymphoma
Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Anna Pawlowska, MD specialize in?
Is Anna Pawlowska, MD currently recruiting for clinical trials?
Are there any treatments that Anna Pawlowska, MD has studied deeply?
What is the best way to schedule an appointment with Anna Pawlowska, MD?
What is the office address of Anna Pawlowska, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.